{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:03:56Z","timestamp":1793300636671,"version":"4.5.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Govt. of India","award":["ECR\/2016\/000965"],"award-info":[{"award-number":["ECR\/2016\/000965"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02053-2","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T04:01:21Z","timestamp":1684728081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC)"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3118-161X","authenticated-orcid":false,"given":"Nikhil","family":"Chandnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-9553","authenticated-orcid":false,"given":"Vedika Shrirang","family":"Choudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-7592","authenticated-orcid":false,"given":"Rajat","family":"Talukdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7496-3155","authenticated-orcid":false,"given":"Sudeshna","family":"Rakshit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3035-6190","authenticated-orcid":false,"given":"Geetha","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9521-0072","authenticated-orcid":false,"given":"Shiuli","family":"Guchait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-1389","authenticated-orcid":false,"given":"Ishika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-8513","authenticated-orcid":false,"given":"Melvin","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-6688","authenticated-orcid":false,"given":"Koustav","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"2053_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12079-017-0418-2","volume":"12","author":"B Chen","year":"2018","unstructured":"Chen B, Zeng C, Ye Y, et al. Promoter methylation of TCF21 may repress autophagy in the progression of lung cancer. J Cell Commun Signal. 2018;12:423\u201332. https:\/\/doi.org\/10.1007\/s12079-017-0418-2.","journal-title":"J Cell Commun Signal"},{"issue":"3","key":"2053_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288\u2013300. https:\/\/doi.org\/10.21037\/tlcr.2016.06.07.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"2053_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/carcin\/bgp220","volume":"31","author":"S Sharma","year":"2009","unstructured":"Sharma S, Kelly T, Jones P. Epigenetics in cancer. Carcinogenesis. 2009;31(1):27\u201336. https:\/\/doi.org\/10.1093\/carcin\/bgp220.","journal-title":"Carcinogenesis"},{"key":"2053_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/4273943","volume":"4273943","author":"P Pandya","year":"2016","unstructured":"Pandya P, Murray M, Pollok K, Renbarger J. The immune system in cancer pathogenesis: potential therapeutic approaches. J Immunol Res. 2016;4273943:1\u201313. https:\/\/doi.org\/10.1155\/2016\/4273943.","journal-title":"J Immunol Res"},{"issue":"5","key":"2053_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ccr.2007.10.016","volume":"12","author":"J Yu","year":"2007","unstructured":"Yu J, et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 2007;12(5):419\u201331. https:\/\/doi.org\/10.1016\/j.ccr.2007.10.016.","journal-title":"Cancer Cell"},{"issue":"58","key":"2053_CR6","doi-asserted-by":"publisher","first-page":"7274","DOI":"10.1038\/onc.2008.333","volume":"27","author":"Q Cao","year":"2008","unstructured":"Cao Q, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008;27(58):7274\u201384. https:\/\/doi.org\/10.1038\/onc.2008.333.","journal-title":"Oncogene"},{"issue":"6907","key":"2053_CR7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature01042","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624\u20139. https:\/\/doi.org\/10.1038\/nature01042.","journal-title":"Nature"},{"issue":"15","key":"2053_CR8","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2009-07-233858","volume":"115","author":"TA Paul","year":"2010","unstructured":"Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood. 2010;115(15):3098\u2013108. https:\/\/doi.org\/10.1182\/blood-2009-07-233858.","journal-title":"Blood"},{"issue":"5","key":"2053_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1101\/gad.415507","volume":"21","author":"AP Bracken","year":"2007","unstructured":"Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 2007;21(5):525\u201330. https:\/\/doi.org\/10.1101\/gad.415507.","journal-title":"Genes Dev"},{"issue":"2","key":"2053_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2012.08.003","volume":"78","author":"J Kikuchi","year":"2012","unstructured":"Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara- Konishi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012;78(2):138\u201343. https:\/\/doi.org\/10.1016\/j.lungcan.2012.08.003.","journal-title":"Lung Cancer"},{"issue":"5","key":"2053_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/cdd.2009.162","volume":"17","author":"ZL Wu","year":"2010","unstructured":"Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ. 2010;17(5):801\u201310. https:\/\/doi.org\/10.1038\/cdd.2009.162.","journal-title":"Cell Death Differ"},{"key":"2053_CR12","doi-asserted-by":"publisher","first-page":"7274","DOI":"10.1038\/onc.2008.333","volume":"27","author":"Q Cao","year":"2008","unstructured":"Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008;27:7274\u201384.","journal-title":"Oncogene"},{"issue":"4","key":"2053_CR13","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1349-7006.2008.00743.x","volume":"99","author":"S Fujii","year":"2008","unstructured":"Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates Ecadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci. 2008;99(4):738\u201346. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00743.x.","journal-title":"Cancer Sci"},{"issue":"1","key":"2053_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1440-1746.2010.06447.x","volume":"26","author":"DP Tsang","year":"2011","unstructured":"Tsang DP, Cheng AS. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol. 2011;26(1):19\u201327. https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06447.x.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"2053_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/bjc.2011.551","volume":"106","author":"CJ Chang","year":"2012","unstructured":"Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer. 2012;106(2):243\u20137. https:\/\/doi.org\/10.1038\/bjc.2011.551.","journal-title":"Br J Cancer"},{"issue":"3","key":"2053_CR16","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1158\/1940-6207.CAPR-11-0414","volume":"5","author":"H Li","year":"2012","unstructured":"Li H, Bitler BG, Vathipadiekal V, et al. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genomewide approaches. Cancer Prev Res. 2012;5(3):484\u201391. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-11-0414.","journal-title":"Cancer Prev Res"},{"key":"2053_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fimmu.2016.00172","volume":"7","author":"T Karantanos","year":"2016","unstructured":"Karantanos T, Christofides A, Bardhan K, Li L, Boussiotis V. Regulation of T cell differentiation and function by EZH2. Front Immunol. 2016;7:346. https:\/\/doi.org\/10.3389\/fimmu.2016.00172.","journal-title":"Front Immunol"},{"issue":"5","key":"2053_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.immuni.2013.09.012","volume":"39","author":"D Tumes","year":"2013","unstructured":"Tumes D, Onodera A, Suzuki A, Shinoda K, Endo Y, Iwamura C, Hosokawa H, Koseki H, Tokoyoda K, Suzuki Y, Motohashi S, Nakayama T. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4+ T helper type 1 and type 2 cells. Immunity. 2013;39(5):819\u201332. https:\/\/doi.org\/10.1016\/j.immuni.2013.09.012.","journal-title":"Immunity"},{"issue":"2","key":"2053_CR19","doi-asserted-by":"publisher","first-page":"F49","DOI":"10.1016\/S0304-419X(96)00044-3","volume":"1332","author":"Y Shi","year":"1997","unstructured":"Shi Y, Lee JS, Galvin KM. Everything you have ever wanted to know about Yin Yang 1. Biochem Biophys Acta. 1997;1332(2):F49\u201366. https:\/\/doi.org\/10.1016\/S0304-419X(96)00044-3.","journal-title":"Biochem Biophys Acta"},{"issue":"2","key":"2053_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0378-1119(99)00261-9","volume":"236","author":"MJ Thomas","year":"1999","unstructured":"Thomas MJ, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene. 1999;236(2):197\u2013208. https:\/\/doi.org\/10.1016\/S0378-1119(99)00261-9.","journal-title":"Gene"},{"issue":"8","key":"2053_CR21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/sj.onc.1209080","volume":"25","author":"S Gordon","year":"2006","unstructured":"Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006;25(8):1125\u201342. https:\/\/doi.org\/10.1038\/sj.onc.1209080.","journal-title":"Oncogene"},{"issue":"23","key":"2053_CR22","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1128\/MCB.00679-09","volume":"29","author":"S Wu","year":"2009","unstructured":"Wu S, Hu YC, Liu H, Shi Y. Loss of YY1 impacts the heterochromatic state and meiotic double-strand breaks during mouse spermatogenesis. Mol Cell Biol. 2009;29(23):6245\u201356. https:\/\/doi.org\/10.1128\/MCB.00679-09.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2053_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1073\/pnas.1214682110","volume":"110","author":"S Hwang","year":"2012","unstructured":"Hwang S, Kim Y, Lee S, Jang S, Kim M, Koh B, Lee W, Kim J, Souabni A, Busslinger M, Lee G. Transcription factor YY1 is essential for regulation of the Th2 cytokine locus and for Th2 cell differentiation. Proc Natl Acad Sci. 2012;110(1):276\u201381. https:\/\/doi.org\/10.1073\/pnas.1214682110.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"2053_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/path.4688","volume":"238","author":"D Tsang","year":"2016","unstructured":"Tsang D, Wu W, Kang W, Lee Y, Wu F, Yu Z, Xiong L, Chan A, Tong J, Yang W, Li M, Lau S, Li X, Lee S, Yang Y, Lai P, Yu D, Xu G, Lo K, Chan M, Wang H, Lee T, Yu J, Wong N, Yip K, To K, Cheng A. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-\u03baB in hepatocellular carcinoma. J Pathol. 2016;238(5):651\u201364. https:\/\/doi.org\/10.1002\/path.4688.","journal-title":"J Pathol"},{"key":"2053_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2022.152259","author":"R Pal","year":"2022","unstructured":"Pal R, Rakshit S, Shanmugam G, Paul N, Bhattacharya D, Chatterjee A, Singh A, George M, Sarkar K. Involvement of xeroderma pigmentosum complementation group G (XPG) in epigenetic regulation of T-helper (TH) cell differentiation during breast cancer. Immunobiology. 2022. https:\/\/doi.org\/10.1016\/j.imbio.2022.152259.","journal-title":"Immunobiology"},{"issue":"37","key":"2053_CR26","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1126\/scitranslmed.3000813","volume":"2","author":"M Taylor","year":"2010","unstructured":"Taylor M, Sadhukhan S, Kottangada P, Ramgopal A, Sarkar K, D\u2019Silva S, Selvakumar A, Candotti F, Vyas Y. Nuclear role of WASp in the pathogenesis of dysregulated TH1 immunity in human Wiskott\u2013Aldrich syndrome. Sci Transl Med. 2010;2(37):3744\u20133744. https:\/\/doi.org\/10.1126\/scitranslmed.3000813.","journal-title":"Sci Transl Med"},{"issue":"23","key":"2053_CR27","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2014-07-587642","volume":"124","author":"K Sarkar","year":"2014","unstructured":"Sarkar K, Sadhukhan S, Han S, Vyas Y. Disruption of hSWI\/SNF complexes in T cells by WAS mutations distinguishes X-linked thrombocytopenia from Wiskott\u2013Aldrich syndrome. Blood. 2014;124(23):3409\u201319. https:\/\/doi.org\/10.1182\/blood-2014-07-587642.","journal-title":"Blood"},{"issue":"1","key":"2053_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jaci.2017.11.023","volume":"142","author":"K Sarkar","year":"2018","unstructured":"Sarkar K, Han S, Wen K, Ochs H, Dupr\u00e9 L, Seidman M, Vyas Y. R-loops cause genomic instability in T helper lymphocytes from patients with Wiskott\u2013Aldrich syndrome. J Allergy Clin Immunol. 2018;142(1):219\u201334. https:\/\/doi.org\/10.1016\/j.jaci.2017.11.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"2053_CR29","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1182\/blood-2015-05-646182","volume":"126","author":"K Sarkar","year":"2015","unstructured":"Sarkar K, Sadhukhan S, Han S, Vyas Y. SUMOylation-disrupting WAS mutation converts WASp from a transcriptional activator to a repressor of NF- B response genes in T cells. Blood. 2015;126(14):1670\u201382. https:\/\/doi.org\/10.1182\/blood-2015-05-646182.","journal-title":"Blood"},{"issue":"10","key":"2053_CR30","doi-asserted-by":"publisher","first-page":"101189","DOI":"10.1016\/j.tranon.2021.101189","volume":"14","author":"S Rakshit","year":"2021","unstructured":"Rakshit S, Sunny JS, George M, Hanna LE, Sarkar K. R-loop modulated epigenetic regulation in T helper cells mechanistically associates coronary artery disease and non-small cell lung cancer. Transl oncol. 2021;14(10):101189. https:\/\/doi.org\/10.1016\/j.tranon.2021.101189.","journal-title":"Transl oncol"},{"key":"2053_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04130-x","author":"S Rakshit","year":"2022","unstructured":"Rakshit S, Sunny JS, George M, Hanna LE, Leela KV, Sarkar K. T helper cell-mediated epitranscriptomic regulation via m6A RNA methylation bridges link between coronary artery disease and invasive ductal carcinoma. J Cancer Res Clin Oncol. 2022. https:\/\/doi.org\/10.1007\/s00432-022-04130-x.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2053_CR32","doi-asserted-by":"publisher","first-page":"741302","DOI":"10.3389\/fimmu.2021.741302","volume":"12","author":"J Huang","year":"2021","unstructured":"Huang J, Zhang J, Guo Z, Li C, Tan Z, Wang J, Yang J, Xue L. Easy or not-the advances of EZH2 in regulating T cell development, differentiation, and activation in antitumor immunity. Front Immunol. 2021;12:741302. https:\/\/doi.org\/10.3389\/fimmu.2021.741302.","journal-title":"Front Immunol"},{"issue":"22","key":"2053_CR33","doi-asserted-by":"publisher","first-page":"10657","DOI":"10.1158\/0008-5472.CAN-07-2498","volume":"67","author":"J Yu","year":"2007","unstructured":"Yu J, Yu J, Rhodes DR, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Can Res. 2007;67(22):10657\u201363. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2498.","journal-title":"Can Res"},{"issue":"5","key":"2053_CR34","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/pros.20550","volume":"67","author":"RJ Bryant","year":"2007","unstructured":"Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate. 2007;67(5):547\u201356. https:\/\/doi.org\/10.1002\/pros.20550.","journal-title":"Prostate"},{"issue":"3","key":"2053_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/pros.20705","volume":"68","author":"RJ Bryant","year":"2008","unstructured":"Bryant RJ, Winder SJ, Cross SS, Hamdy FC, Cunliffe VT. The polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells. Prostate. 2008;68(3):255\u201363. https:\/\/doi.org\/10.1002\/pros.20705.","journal-title":"Prostate"},{"issue":"1\u20132","key":"2053_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","volume":"647","author":"JA Simon","year":"2008","unstructured":"Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res Fundam Mol Mech Mutagen. 2008;647(1\u20132):21\u20139. https:\/\/doi.org\/10.1016\/j.mrfmmm.2008.07.010.","journal-title":"Mutat Res Fundam Mol Mech Mutagen"},{"issue":"16","key":"2053_CR37","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.4161\/cc.5.16.3222","volume":"5","author":"OP Berezovska","year":"2006","unstructured":"Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle. 2006;5(16):1886\u2013901. https:\/\/doi.org\/10.4161\/cc.5.16.3222.","journal-title":"Cell Cycle"},{"issue":"20","key":"2053_CR38","doi-asserted-by":"publisher","first-page":"11606","DOI":"10.1073\/pnas.1933744100","volume":"100","author":"CG Kleer","year":"2003","unstructured":"Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003;100(20):11606\u201311. https:\/\/doi.org\/10.1073\/pnas.1933744100.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2053_CR39","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1349-7006.2006.00203.x","volume":"97","author":"Y Matsukawa","year":"2006","unstructured":"Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006;97(6):484\u201391. https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00203.x.","journal-title":"Cancer Sci"},{"issue":"19","key":"2053_CR40","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.3748\/wjg.v16.i19.2421","volume":"16","author":"CG Wang","year":"2010","unstructured":"Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol. 2010;16(19):2421\u20137. https:\/\/doi.org\/10.3748\/wjg.v16.i19.2421.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"2053_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","volume":"18","author":"C Lu","year":"2010","unstructured":"Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010;18(2):185\u201397. https:\/\/doi.org\/10.1016\/j.ccr.2010.06.016.","journal-title":"Cancer Cell"},{"issue":"1","key":"2053_CR42","doi-asserted-by":"publisher","first-page":"e16282","DOI":"10.1371\/journal.pone.0016282","volume":"6","author":"M Smits","year":"2011","unstructured":"Smits M, Mir SE, Nilsson RJ, et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS ONE. 2011;6(1):e16282. https:\/\/doi.org\/10.1371\/journal.pone.0016282.","journal-title":"PLoS ONE"},{"issue":"23","key":"2053_CR43","doi-asserted-by":"publisher","first-page":"6556","DOI":"10.1158\/1078-0432.CCR-12-3946","volume":"19","author":"C Behrens","year":"2013","unstructured":"Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, et al. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 2013;19(23):6556\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3946.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2053_CR44","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1002\/cncr.25128","volume":"116","author":"J Kikuchi","year":"2010","unstructured":"Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, Kaga K, Matsuno Y, Nishimura M, Dosaka-Akita H. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer. 2010;116(12):3015\u201324. https:\/\/doi.org\/10.1002\/cncr.25128.","journal-title":"Cancer"},{"issue":"7","key":"2053_CR45","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/j\/1349-7006.2011.01958x","volume":"102","author":"M Takawa","year":"2011","unstructured":"Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 2011;102(7):1298\u2013305. https:\/\/doi.org\/10.1111\/j\/1349-7006.2011.01958x.","journal-title":"Cancer Sci"},{"issue":"6","key":"2053_CR46","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/cncr.26441","volume":"118","author":"Huqun","year":"2012","unstructured":"Huqun, Ishikawa R, Zhang J, Miyazawa H, Shimizu Y, Hagiwara K, Koyama N. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer. 2012;118(6):1599\u2013606. https:\/\/doi.org\/10.1002\/cncr.26441.","journal-title":"Cancer"},{"issue":"12","key":"2053_CR47","doi-asserted-by":"publisher","first-page":"e52984","DOI":"10.1371\/journal.pone.0052948","volume":"7","author":"W Cao","year":"2012","unstructured":"Cao W, Ribeiro Rde O, Liu D, Saintigny P, Xia R, Xue Y, Lin R, Mao L, Ren H. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS ONE. 2012;7(12):e52984. https:\/\/doi.org\/10.1371\/journal.pone.0052948.","journal-title":"PLoS ONE"},{"issue":"48","key":"2053_CR48","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1038\/onc.2015.38","volume":"34","author":"JT Poirier","year":"2015","unstructured":"Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, Rudin CM. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene. 2015;34(48):5869\u201378. https:\/\/doi.org\/10.1038\/onc.2015.38.","journal-title":"Oncogene"},{"issue":"17","key":"2053_CR49","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1016\/j.febslet.2014.05.057","volume":"588","author":"Z Li","year":"2014","unstructured":"Li Z, Xu L, Tang N, Xu Y, Shen XYS, Niu X, Lu S, Chen Z. The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2. FEBS Lett. 2014;588(17):3000\u20137. https:\/\/doi.org\/10.1016\/j.febslet.2014.05.057.","journal-title":"FEBS Lett"},{"issue":"2","key":"2053_CR50","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12094-0120897-9","volume":"15","author":"L Wan","year":"2013","unstructured":"Wan L, Li X, Shen H, Bai X. Quantitative analysis of EZH2 expression and its correlations with lung cancer patients\u2019 clinical pathological characteristics. Clin Transl Oncol. 2013;15(2):132\u20138. https:\/\/doi.org\/10.1007\/s12094-0120897-9.","journal-title":"Clin Transl Oncol"},{"issue":"23","key":"2053_CR51","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1038\/onc.2010.635","volume":"30","author":"B Testoni","year":"2011","unstructured":"Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. p53-paralog DNp73 oncogene is repressed by IFNalpha\/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene. 2011;30(23):2670\u20138. https:\/\/doi.org\/10.1038\/onc.2010.635.","journal-title":"Oncogene"},{"issue":"2","key":"2053_CR52","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","volume":"24","author":"IM Bachmann","year":"2006","unstructured":"Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268\u201373. https:\/\/doi.org\/10.1200\/JCO.2005.01.5180.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2053_CR53","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3892\/or.2012.1787","volume":"28","author":"Y Lv","year":"2012","unstructured":"Lv Y, Yuan C, Xiao X, Wang X, Ji X, Yu H, et al. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma. Oncol Rep. 2012;28(1):147\u201354. https:\/\/doi.org\/10.3892\/or.2012.1787.","journal-title":"Oncol Rep"},{"issue":"9","key":"2053_CR54","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-10-2156","volume":"17","author":"A Chase","year":"2011","unstructured":"Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17(9):2613\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2156.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2053_CR55","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/cas.14069","volume":"110","author":"Y Ohue","year":"2019","unstructured":"Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110(7):2080\u20139. https:\/\/doi.org\/10.1111\/cas.14069.","journal-title":"Cancer Sci"},{"issue":"10","key":"2053_CR56","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.3389\/fimmu.2019.02226","volume":"24","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zhou X. Foxp3 instability helps ttregs distinguish self and non-self. Front Immunol. 2019;24(10):2226. https:\/\/doi.org\/10.3389\/fimmu.2019.02226.","journal-title":"Front Immunol"},{"issue":"4","key":"2053_CR57","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2011.03.018","volume":"34","author":"A Chaudhry","year":"2011","unstructured":"Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Br\u00fcning JC, M\u00fcller W, Rudensky AY. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011;34(4):566\u201378. https:\/\/doi.org\/10.1016\/j.immuni.2011.03.018.","journal-title":"Immunity"},{"issue":"9","key":"2053_CR58","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"4","author":"F Castro","year":"2018","unstructured":"Castro F, Cardoso AP, Gon\u00e7alves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;4(9):847. https:\/\/doi.org\/10.3389\/fimmu.2018.00847.","journal-title":"Front Immunol"},{"issue":"3","key":"2053_CR59","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4143\/crt.2014.46.3.297","volume":"46","author":"Q Li","year":"2014","unstructured":"Li Q, Liu L, Zhang Q, Liu S, Ge D, You Z. Interleukin-17 indirectly promotes M2 macrophage differentiation through stimulation of COX-2\/PGE2 pathway in the cancer cells. Cancer Res Treat: Off J Korean Cancer Assoc. 2014;46(3):297\u2013306. https:\/\/doi.org\/10.4143\/crt.2014.46.3.297.","journal-title":"Cancer Res Treat: Off J Korean Cancer Assoc"},{"issue":"14","key":"2053_CR60","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","volume":"19","author":"E Guenova","year":"2013","unstructured":"Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, Fisher DC. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphomath2 cytokines from malignant cells suppress TH1 in L-CTCL. Clin Cancer Res. 2013;19(14):3755\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3488.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2053_CR61","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1093\/emboj\/20.17.4912","volume":"20","author":"A Damalas","year":"2001","unstructured":"Damalas A, Kahan S, Shtutman M, Ben-Ze\u2019ev A, Oren M. Deregulated \u03b2-catenin induces a p53-and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J. 2001;20(17):4912\u201322. https:\/\/doi.org\/10.1093\/emboj\/20.17.4912.","journal-title":"EMBO J"},{"key":"2053_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0122-2","author":"L Gan","year":"2018","unstructured":"Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018. https:\/\/doi.org\/10.1186\/s40364-018-0122-2.","journal-title":"Biomark Res"},{"issue":"26","key":"2053_CR63","doi-asserted-by":"publisher","first-page":"24428","DOI":"10.1074\/jbc.M503790200","volume":"280","author":"DY Begon","year":"2005","unstructured":"Begon DY, Delacroix L, Vernimmen D, Jackers P, Winkler R. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem. 2005;280(26):24428\u201334. https:\/\/doi.org\/10.1074\/jbc.M503790200.","journal-title":"J Biol Chem"},{"issue":"1","key":"2053_CR64","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3892\/ijo.27.1.131","volume":"27","author":"D Seligson","year":"2005","unstructured":"Seligson D, Horvath S, Huerta-Yepez S, et al. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol. 2005;27(1):131\u201341. https:\/\/doi.org\/10.3892\/ijo.27.1.131.","journal-title":"Int J Oncol"},{"issue":"3","key":"2053_CR65","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1182\/blood-2002-04-1207","volume":"101","author":"SJ Erkeland","year":"2003","unstructured":"Erkeland SJ, Valkhof M, Heijmans-Antonissen C, et al. The gene encoding the transcriptional regulator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation. Blood. 2003;101(3):1111\u20137. https:\/\/doi.org\/10.1182\/blood-2002-04-1207.","journal-title":"Blood"},{"issue":"15","key":"2053_CR66","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1016\/j.ejca.2006.06.008","volume":"42","author":"F de Nigris","year":"2006","unstructured":"de Nigris F, Botti C, de Chiara A, et al. Expression of transcription factor Yin Yang 1 in human osteosarcomas. Eur J Cancer. 2006;42(15):2420\u20134. https:\/\/doi.org\/10.1016\/j.ejca.2006.06.008.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2053_CR67","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/sj.onc.1209804","volume":"26","author":"F de Nigris","year":"2007","unstructured":"de Nigris F, Botti C, Rossiello R, Crimi E, Sica V, Napoli C. Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha3beta1- integrin in tumour cells. Oncogene. 2007;26(3):382\u201394. https:\/\/doi.org\/10.1038\/sj.onc.1209804.","journal-title":"Oncogene"},{"issue":"2","key":"2053_CR68","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1080\/07357900802210760","volume":"27","author":"S Baritaki","year":"2009","unstructured":"Baritaki S, Chatzinikola AM, Vakis AF, et al. YY1 over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levels. Cancer Invest. 2009;27(2):184\u201392. https:\/\/doi.org\/10.1080\/07357900802210760.","journal-title":"Cancer Invest"},{"issue":"10","key":"2053_CR69","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-04-2398","volume":"11","author":"A Berchuck","year":"2005","unstructured":"Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11(10):3686\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2398.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2053_CR70","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1182\/blood-2006-09-046391","volume":"109","author":"E Sakhinia","year":"2007","unstructured":"Sakhinia E, Glennie C, Hoyland JA, et al. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood. 2007;109(9):3922\u20138. https:\/\/doi.org\/10.1182\/blood-2006-09-046391.","journal-title":"Blood"},{"issue":"5","key":"2053_CR71","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3892\/ijo_00000270","volume":"34","author":"D Chinnappan","year":"2009","unstructured":"Chinnappan D, Xiao D, Ratnasari A, Andry C, King TC, Weber HC. Transcription factor YY1 expression in human gastrointestinal cancer cells. Int J Oncol. 2009;34(5):1417\u201323. https:\/\/doi.org\/10.3892\/ijo_00000270.","journal-title":"Int J Oncol"},{"issue":"19","key":"2053_CR72","doi-asserted-by":"publisher","first-page":"28498","DOI":"10.18632\/oncotarget.8654","volume":"7","author":"JJ Zhang","year":"2016","unstructured":"Zhang JJ, Zhu Y, Yang C, Liu X, Peng YP, Jiang KR, et al. Yin Yang-1 increases apoptosis through Bax activation in pancreatic cancer cells. Oncotarget. 2016;7(19):28498\u2013509. https:\/\/doi.org\/10.18632\/oncotarget.8654.","journal-title":"Oncotarget"},{"issue":"6","key":"2053_CR73","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1158\/0008-5472.CAN-07-5582","volume":"68","author":"F de Nigris","year":"2008","unstructured":"de Nigris F, Rossiello R, Schiano C, et al. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4\/angiogenesis and metastasis. Can Res. 2008;68(6):1797\u2013808. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5582.","journal-title":"Can Res"},{"issue":"15","key":"2053_CR74","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1200\/JCO.2008.17.9762","volume":"27","author":"FA Monzon","year":"2009","unstructured":"Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, Sciulli C, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol. 2009;27(15):2503\u20138. https:\/\/doi.org\/10.1200\/JCO.2008.17.9762.","journal-title":"J Clin Oncol"},{"key":"2053_CR75","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.biopha.2016.10.040","volume":"84","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Sun Z, Fu T, Liu C, Liu Y, Lin Y. The microRNA-635 suppresses tumorigenesis in non-small cell lung cancer. Biomed Pharmacother. 2016;84:1274\u201381. https:\/\/doi.org\/10.1016\/j.biopha.2016.10.040.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"2053_CR76","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4161\/cc.9.3.10588","volume":"9","author":"A Zaravinos","year":"2010","unstructured":"Zaravinos A, Spandidos DA. Yin yang 1 expression in human tumors. Cell Cycle. 2010;9(3):512\u201322. https:\/\/doi.org\/10.4161\/cc.9.3.10588.","journal-title":"Cell Cycle"},{"issue":"11","key":"2053_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/dna.2017.3857","volume":"36","author":"T Huang","year":"2017","unstructured":"Huang T, Wang G, Yang L, Peng B, Wen Y, Ding G, Wang Z. Transcription factor YY1 modulates lung cancer progression by activating lncRNA-PVT1. DNA Cell Biol. 2017;36(11):1\u201312. https:\/\/doi.org\/10.1089\/dna.2017.3857.","journal-title":"DNA Cell Biol"},{"issue":"6","key":"2053_CR78","doi-asserted-by":"publisher","first-page":"e68226","DOI":"10.1371\/journal.pone.0068226","volume":"8","author":"SL Au","year":"2013","unstructured":"Au SL, Wong CC, Lee JM, Wong C, Ng IO. EZH2-mediated H3K27me3 is involved in epigenetic repression of deleted in liver cancer 1 in human cancers. PLoS ONE. 2013;8(6):e68226.","journal-title":"PLoS ONE"},{"issue":"4","key":"2053_CR79","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12032-013-0713-6","volume":"30","author":"C Xu","year":"2013","unstructured":"Xu C, Hou Z, Zhan P, Zhao W, Chang C, Zou J, Hu H, Zhang Y, Yao X, Yu L, et al. EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer. Med Oncol. 2013;30(4):713. https:\/\/doi.org\/10.1007\/s12032-013-0713-6.","journal-title":"Med Oncol"},{"issue":"1","key":"2053_CR80","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1356-2354.2009.01148x","volume":"20","author":"YB Zhang","year":"2010","unstructured":"Zhang YB, Niu HT, Chang JW, Dong GL, Ma XB. EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines. Eur J Cancer Care. 2010;20(1):106\u201312. https:\/\/doi.org\/10.1111\/j.1356-2354.2009.01148x.","journal-title":"Eur J Cancer Care"},{"issue":"3","key":"2053_CR81","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.celrep.2014.12.028","volume":"10","author":"NA de Vries","year":"2015","unstructured":"de Vries NA, Hulsman D, Akhtar W, et al. Prolonged Ezh2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progression. Cell Report. 2015;10(3):383\u201397. https:\/\/doi.org\/10.1016\/j.celrep.2014.12.028.","journal-title":"Cell Report"},{"issue":"18","key":"2053_CR82","doi-asserted-by":"publisher","first-page":"26535","DOI":"10.18632\/oncotarget.8532","volume":"7","author":"GQ Wu","year":"2016","unstructured":"Wu GQ, et al. Anti-cancer effects of curcumin on lung cancer through the inhibition of EZH2 and NOTCH1. Oncotarget. 2016;7(18):26535\u201350. https:\/\/doi.org\/10.18632\/oncotarget.8532.","journal-title":"Oncotarget"},{"issue":"5","key":"2053_CR83","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.immuni.2013.09.012","volume":"39","author":"DJ Tumes","year":"2013","unstructured":"Tumes DJ, et al. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4+ T helper type 1 and type 2 cells. Immunity. 2013;39(5):819\u201332. https:\/\/doi.org\/10.1016\/j.immuni.2013.09.012.","journal-title":"Immunity"},{"issue":"13","key":"2053_CR84","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4255\/mcpharmacol.09.20","volume":"1","author":"G Sui","year":"2009","unstructured":"Sui G. The regulation of YY1 in tumorigenesis and its targeting potential in cancer therapy. Mol Cell Pharmacol. 2009;1(13):157\u201376. https:\/\/doi.org\/10.4255\/mcpharmacol.09.20.","journal-title":"Mol Cell Pharmacol"},{"issue":"8","key":"2053_CR85","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/emboj.2013.66","volume":"32","author":"X Pan","year":"2013","unstructured":"Pan X, Papasani M, Hao Y, et al. YY1 controls Ig\u03ba repertoire and B-cell development, and localizes with condensin on the Ig\u03ba locus. EMBO J. 2013;32(8):1168\u201382. https:\/\/doi.org\/10.1038\/emboj.2013.66.","journal-title":"EMBO J"},{"issue":"4","key":"2053_CR86","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1093\/nar\/gkt1187","volume":"42","author":"A Basu","year":"2014","unstructured":"Basu A, Wilkinson FH, Colavita K, et al. YY1 DNA binding and interaction with YAF2 is essential for polycomb recruitment. Nucleic Acids Res. 2014;42(4):2208\u201323. https:\/\/doi.org\/10.1093\/nar\/gkt1187.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"2053_CR87","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/path.4688","volume":"238","author":"DPF Tsang","year":"2016","unstructured":"Tsang DPF, et al. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-\u03baB in hepatocellular carcinoma. J Pathol. 2016;238(5):651\u201364. https:\/\/doi.org\/10.1002\/path.4688.","journal-title":"J Pathol"},{"issue":"9","key":"2053_CR88","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/ijc.30265","volume":"139","author":"T Ghosh","year":"2016","unstructured":"Ghosh T, Barik S, Bhuniya A, Dhar J, Dasgupta S, Ghosh S, Sarkar M, Guha I, Sarkar K, Chakrabarti P, Saha B. Tumor-associated mesenchymal stem cells inhibit na\u00efve T cell expansion by blocking cysteine export from dendritic cells. Int J Cancer. 2016;139(9):2068\u201381. https:\/\/doi.org\/10.1002\/ijc.30265.","journal-title":"Int J Cancer"},{"issue":"4","key":"2053_CR89","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1007\/s11033-021-06379-w","volume":"48","author":"J Obradovic","year":"2021","unstructured":"Obradovic J, Todosijevic J, Jurisic V. Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review. Mol Biol Rep. 2021;48(4):3593\u2013604. https:\/\/doi.org\/10.1007\/s11033-021-06379-w.","journal-title":"Mol Biol Rep"},{"issue":"2","key":"2053_CR90","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3892\/ol.2022.13649","volume":"25","author":"J Obradovic","year":"2022","unstructured":"Obradovic J, Todosijevic J, Jurisic V. Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: a systematic review and meta-analysis. Oncol Lett. 2022;25(2):62. https:\/\/doi.org\/10.3892\/ol.2022.13649.","journal-title":"Oncol Lett"},{"key":"2053_CR91","doi-asserted-by":"publisher","first-page":"1973241","DOI":"10.1155\/2020\/1973241","volume":"2020","author":"V Jurisic","year":"2020","unstructured":"Jurisic V, Vukovic V, Obradovic J, Gulyaeva LF, Kushlinskii NE, Djordjevi\u0107 N. EGFR polymorphism and survival of NSCLC patients treated with TKIs: a systematic review and meta-analysis. J oncol. 2020;2020:1973241. https:\/\/doi.org\/10.1155\/2020\/1973241.","journal-title":"J oncol"},{"issue":"9","key":"2053_CR92","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/14789450.2020.1845654","volume":"17","author":"V Jurisic","year":"2020","unstructured":"Jurisic V. Multiomic analysis of cytokines in immuno-oncology. Expert Rev Proteomics. 2020;17(9):663\u201374. https:\/\/doi.org\/10.1080\/14789450.2020.1845654.","journal-title":"Expert Rev Proteomics"},{"key":"2053_CR93","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cyto.2019.02.001","volume":"117","author":"GM Konjevi\u0107","year":"2019","unstructured":"Konjevi\u0107 GM, Vuleti\u0107 AM, Mirja\u010di\u0107 Martinovi\u0107 KM, Larsen AK, Juri\u0161i\u0107 VB. The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine. 2019;117:30\u201340. https:\/\/doi.org\/10.1016\/j.cyto.2019.02.001.","journal-title":"Cytokine"},{"key":"2053_CR94","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-94-017-7215-0_8","volume":"867","author":"V Jurisic","year":"2015","unstructured":"Jurisic V, Radenkovic S, Konjevic G. The actual role of LDH as tumor marker, biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:115\u201324. https:\/\/doi.org\/10.1007\/978-94-017-7215-0_8.","journal-title":"Adv Exp Med Biol"},{"issue":"1\u20132","key":"2053_CR95","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s0022-1759(96)00194-9","volume":"200","author":"G Konjevi\u0107","year":"1997","unstructured":"Konjevi\u0107 G, Jurisi\u0107 V, Spuzi\u0107 I. Corrections to the original lactate dehydrogenase (LDH) release assay for the evaluation of NK cell cytotoxicity. J Immunol Methods. 1997;200(1\u20132):199\u2013201. https:\/\/doi.org\/10.1016\/s0022-1759(96)00194-9.","journal-title":"J Immunol Methods"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02053-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02053-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02053-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T21:15:27Z","timestamp":1687900527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02053-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":95,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["2053"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02053-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"22 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For molecular studies involved in the current research project, blood samples of normal subjects and NSCLC patients were collected and handled under the protocol approved by the institutional ethics committee at SRM Medical College Hospital, Kattankulathur, Cheenai, Tamil Nadu, India (Ethics Clearance Number 2909\/IEC\/2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Signed informed consent was collected from each NSCLC patient and normal individuals who took part in the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"185"}}